ES8502340A1 - Procedimiento de obtencion deuna vacuna que contiene vitaminas y compuestos de cinc y de selenio fisiologicamente compatibles. - Google Patents

Procedimiento de obtencion deuna vacuna que contiene vitaminas y compuestos de cinc y de selenio fisiologicamente compatibles.

Info

Publication number
ES8502340A1
ES8502340A1 ES527041A ES527041A ES8502340A1 ES 8502340 A1 ES8502340 A1 ES 8502340A1 ES 527041 A ES527041 A ES 527041A ES 527041 A ES527041 A ES 527041A ES 8502340 A1 ES8502340 A1 ES 8502340A1
Authority
ES
Spain
Prior art keywords
vaccines
additives
vitamins
antigens
absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES527041A
Other languages
English (en)
Other versions
ES527041A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6177517&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8502340(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG filed Critical Bayer AG
Publication of ES527041A0 publication Critical patent/ES527041A0/es
Publication of ES8502340A1 publication Critical patent/ES8502340A1/es
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265Infectious rhinotracheitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE UNA VACUNA QUE CONTIENE VITAMINAS Y COMPUESTOS DE CINC Y DE SELENIO FISIOLOGICAMENTE COMPATIBLES.COMPRENDE LAS ETAPAS: A) COMBINAR ANTIGENOS CON 20.000 A 600.000 UNIDADES DE VITAMINAS A Y D SOLUBLES EN GRASAS; 100 A 1.000 MG DE VITAMINA E Y DE COMPUESTOS DE SELENIO FISIOLOGICAMENTE ACEPTABLES; 50 A 1.000 MG DE COMPUESTOS DE CINC FISIOLOGICAMENTE ACEPTABLES; 20 A 95 PARTES EN PESO DE UN AGENTE PROMOTOR DE LA ABSORCION Y OPCIONALMENTE 0,5 A 50 PARTES EN PESO DE UN ACEITE EXTENDEDOR; B) HOMOGENEIZAR EL PRODUCTO RAULTANTE; Y C) AJUSTAR EL PH DEL PRODUCTO RESULTANTE ENTRE 5 Y 8. COMO ANTIGENOS SE EMPLEAN LOS VIRUS IBR/IPV, PI-3 Y OTROS; COMPUESTOS DE SELENIO SE EMPLEAN, HALUROS DE SELENIO, SELENIDOS Y OTROS; COMPUESTOS DE CINC SE EMPLEAN, HALUROS DE CINC, SULFATO DE CINC Y OTROS; AGENTE PROMOTOR DE LA ABSORCION SE EMPLEA ALCOHOLES, GLICOLES Y OTROS Y COMO AGENTE EXTENDEDOR SE EMPLEA DIMETILSULFOXIDO O ALCOHOL ISOPROPILICO.SE UTILIZA PARA COMBATIR LA PROFILAXISDE LAS ENFERMEDADES POR VIRUS.
ES527041A 1982-11-06 1983-11-04 Procedimiento de obtencion deuna vacuna que contiene vitaminas y compuestos de cinc y de selenio fisiologicamente compatibles. Expired ES8502340A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823241113 DE3241113A1 (de) 1982-11-06 1982-11-06 Vakzinen mit zuschlagstoffen

Publications (2)

Publication Number Publication Date
ES527041A0 ES527041A0 (es) 1985-01-01
ES8502340A1 true ES8502340A1 (es) 1985-01-01

Family

ID=6177517

Family Applications (1)

Application Number Title Priority Date Filing Date
ES527041A Expired ES8502340A1 (es) 1982-11-06 1983-11-04 Procedimiento de obtencion deuna vacuna que contiene vitaminas y compuestos de cinc y de selenio fisiologicamente compatibles.

Country Status (4)

Country Link
US (1) US4698221A (es)
EP (1) EP0108316A3 (es)
DE (1) DE3241113A1 (es)
ES (1) ES8502340A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3710770A1 (de) * 1987-03-31 1988-10-13 Behringwerke Ag Neue alkansaeurealkylester, verfahren zu ihrer herstellung und verwendung von waessrigen emulsionen dieser ester in vaccinen
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
CA2066716A1 (en) * 1989-09-25 1991-03-26 Raymond A. Daynes Use of steroid hormones in compositions for inducing t cell lymphokine production
US5919465A (en) * 1989-09-25 1999-07-06 University Of Utah Research Foundation Methods for augmenting immunological responses through the administration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S)
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
DE4333376C2 (de) * 1993-09-30 1995-09-07 Gerbu Biotechnik Gmbh Mittel zur Steigerung der Ausbeute von Antikörpern in der Immunologie
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
AP2003002867A0 (en) * 2001-03-05 2003-09-30 Forinnova As Immune response potentiation
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
CA2620406A1 (en) 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP1945196A2 (en) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesium-containing polymers for hyperphosphatemia
EP2043627A2 (en) * 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
AU2010203223B9 (en) * 2009-01-05 2015-10-08 Epitogenesis Inc. Adjuvant compositions and methods of use
JP5798356B2 (ja) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
CN103717235A (zh) * 2011-06-24 2014-04-09 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
CN110507606A (zh) * 2012-12-18 2019-11-29 唐纳吉有限公司 透皮的杀寄生虫制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB888180A (es) * 1900-01-01
NL92777C (es) * 1956-07-27 1959-10-16
NL262968A (es) * 1960-04-02 1900-01-01
DE1492179A1 (de) * 1965-12-10 1969-12-18 Schering Ag Verfahren zur Herstellung von perkutan wirksamen Zubereitungen von Impfstoffen
GB1189340A (en) * 1967-09-13 1970-04-22 American Cyanamid Co Antigen-Adjuvant Composition
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3531565A (en) * 1969-09-25 1970-09-29 American Cyanamid Co Stable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acid
BE793530A (nl) * 1971-12-29 1973-06-29 Janssen Pharmaceutica Nv Vaccin-hulpmiddel
US4298601A (en) * 1972-03-06 1981-11-03 Technutra, S.A. Method and formulations for the treatment of obesity
DE2526938C2 (de) * 1975-02-14 1982-04-22 F. Hoffmann-La Roche & Co. AG, 4002 Basel Vitaminpräparate
US4073743A (en) * 1975-04-17 1978-02-14 Merck & Co., Inc. Process for preparing an emulsion
NZ191413A (en) * 1978-09-11 1981-10-19 Ici Australia Ltd Anthelmintic and anticlostridial composition containing a tetramisole salt

Also Published As

Publication number Publication date
EP0108316A3 (de) 1986-10-08
EP0108316A2 (de) 1984-05-16
US4698221A (en) 1987-10-06
ES527041A0 (es) 1985-01-01
DE3241113A1 (de) 1984-05-10

Similar Documents

Publication Publication Date Title
ES8502340A1 (es) Procedimiento de obtencion deuna vacuna que contiene vitaminas y compuestos de cinc y de selenio fisiologicamente compatibles.
DE3261178D1 (en) Polyethers, their preparation and their use as lubricants
IL67826A0 (en) Pyrazolooxazines,pyrazolothiazines and pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
IL70422A0 (en) 1-azolyl-2-aryl-3-fluoroalkan-2-ols,their preparation and microbicidal compositions containing them
DE3363079D1 (en) Lipopeptides, their manufacture and use as emulsifiers
PH19424A (en) 2-substituted 4 amino 6,7 dimethoxyquinolines
DE3373897D1 (en) Amino-triazine derivative, its preparation and its use in heat-curable compositions
EP0105924A4 (en) DRY POWDER WITH IMPROVED FLOW AND COMPRESSION BEHAVIOR AND METHOD FOR PRODUCING THE COMPOSITION.
IT8348155A0 (it) Benzoazacicloalchilspiro-imidazolidine,procedimento per prepararle e composizioni farmaceutiche che le contengono
EP0147437A4 (en) DRY COMPOSITIONS WITH DIRECT COMPRESSION FOR DOSAGE FORMS WITH CONTROLLED ADMINISTRATION.
ZA839534B (en) Substituted phenylsulfonyloxybenzimidazolecarbamates,processes for their preparation and pharmaceutical compositions containing the same
ZA816555B (en) Novel benzoxazolinones,substituted in the 6-position by an amino-alcohol chain or amino-ketone chain,their preparation and their use in pharmaceutical preparations
IT8321720A0 (it) Composizioni di profumo a cessione protratta e un procedimento per laloro preparazione.
IL68586A0 (en) 4-aryl-4-piperidinecarbinols,their preparation and pharmaceutical compositions containing them
DE3363790D1 (en) Azolyl-methyl amines, their preparation and their use in microbicide compositions
IL68699A0 (en) 3-phenoxy-1-azetidinecarboxamides,their preparation and pharmaceutical compositions containing them
IT8225093A0 (it) Stabilizzare le bevande contro la composizione e procedimento per formazione di intorbidimento.
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
MY100792A (en) Vitamin composition with enhances bioavailability
IL70478A0 (en) Substituted azabicycloalkanes,their preparation and pharmaceutical compositions containing them
DE3366170D1 (en) Pyrimidone compounds, their preparation, and pharmaceutical compositions containing them
DE3368199D1 (en) Mixture comprising a central analgesic and vitamin b12, or one of its analogs, as active principles
IL68118A0 (en) Phenoxypropyltriazolyl-ketones and-carbinols,their preparation and their use as fungicides
IT8319143A0 (it) Monoidrati di steroidi, formulazioni che li contengono eprocedimento per la loro preparazione.
GB2147806B (en) Refined detoxified endotoxin compositions